Home

Terumo Corp (TRUMF)

20.58
+2.68 (15.00%)
OP · Last Trade: May 1st, 1:54 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analystbenzinga.com
Inari Medical with strong position in venous thrombectomy. Buy-rated by Needham with a $72 target. Undervalued shares with an 88% gross margin and anticipated double-digit revenue growth.
Via Benzinga · January 23, 2024